Title
In Silico Searching for Alternative Lead Compounds to Treat Type 2 Diabetes through a QSAR and Molecular Dynamics Study
Date Issued
01 January 2022
Access level
open access
Resource Type
journal article
Author(s)
Cabrera N.
Cuesta S.A.
Mora J.R.
Calle L.
Kaunas R.
Publisher(s)
MDPI
Abstract
Free fatty acid receptor 1 (FFA1) stimulates insulin secretion in pancreatic β-cells. An advantage of therapies that target FFA1 is their reduced risk of hypoglycemia relative to common type 2 diabetes treatments. In this work, quantitative structure–activity relationship (QSAR) approach was used to construct models to identify possible FFA1 agonists by applying four different machine-learning algorithms. The best model (M2) meets the Tropsha’s test requirements and has the statistics parameters R2 = 0.843, Q2CV = 0.785, and Q2ext = 0.855. Also, coverage of 100% of the test set based on the applicability domain analysis was obtained. Furthermore, a deep analysis based on the ADME predictions, molecular docking, and molecular dynamics simulations was performed. The lipophilicity and the residue interactions were used as relevant criteria for selecting a candidate from the screening of the DiaNat and DrugBank databases. Finally, the FDA-approved drugs bilastine, bromfenac, and fenofibric acid are suggested as potential and lead FFA1 agonists.
Volume
14
Issue
2
Language
English
OCDE Knowledge area
Química medicinal Endocrinología, Metabolismo (incluyendo diabetes, hormonas)
Scopus EID
2-s2.0-85123127438
Source
Pharmaceutics
ISSN of the container
19994923
Sponsor(s)
Acknowledgments: L.C. is grateful to the Instituto of Biomedicina of Universidad Católica Santiago de Guayaquil (UCSG), J.R.M. is grateful to the USFQ-POLI grants 2021–2022 for the financial support and Universidad del Norte, Colombia. The authors have used the high-performance computing (HPC) system available in both, USFQ, and Uninorte, for the development of this project.
Sources of information: Directorio de Producción Científica Scopus